Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,000 across all filing types
Latest filing 2025-08-12 Major Shareholding Noti…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
EN PR.pdf
Major Shareholding Notification Classification · 1% confidence The document is a 'Transparency notification' regarding FMR LLC's shareholding in UCB SA/NV. It explicitly details the crossing of a 5% voting rights threshold, lists the number of shares held, and provides the chain of controlled undertakings. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2025-08-12 English
FR PR.pdf
Major Shareholding Notification Classification · 1% confidence The document is a formal 'Transparency Notification' (Notification de transparence) regarding a change in significant shareholding by FMR LLC in UCB SA. It explicitly mentions crossing the 5% threshold, details the chain of controlled entities, and provides the number of voting rights. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-08-12 French
NL PR.pdf
Major Shareholding Notification Classification · 1% confidence The document is a 'Transparantieverklaring' (Transparency Declaration) from UCB NV regarding FMR LLC. It details a change in shareholding where FMR LLC crossed the 5% threshold. This is a standard regulatory notification regarding major shareholding ownership. According to the filing definitions, notifications of changes in significant share ownership levels are classified as 'Major Shareholding Notification' (MRQ).
2025-08-12 Dutch
UCB PR HY 2025 ENG.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'UCB Half-Year Report 2025' and contains comprehensive financial data, including revenue, net sales, adjusted EBITDA, and Core EPS for the first half of 2025 compared to 2024. It also provides detailed management commentary, product performance breakdowns, and clinical pipeline updates. As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim / Quarterly Report. H1 2025
2025-07-31 English
UCB PR HY 2025 FR.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive semi-annual report (Rapport semestriel) for UCB, covering financial performance (revenue, EBITDA, EPS), product sales, R&D pipeline updates, and management commentary for the first half of 2025. It contains substantive financial data and analysis, distinguishing it from a mere announcement or press release. It fits the definition of an Interim/Quarterly Report (IR). H1 2025
2025-07-31 French
UCB PR HY 2025 NL.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive half-year financial report (halfjaarverslag) for UCB for the period ending July 31, 2025. It contains detailed financial tables (revenue, EBITDA, earnings per share), analysis of business performance, product-specific sales data, and updates on clinical pipelines and regulatory status. It is not a mere announcement (RPA) as it provides substantive financial data and analysis, nor is it a full annual report (10-K). It fits the definition of an Interim/Quarterly Report (IR). H1 2025
2025-07-31 Dutch

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.